




The relative strengths and weaknesses of Checkpoint Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Checkpoint Therapeutics Inc compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 4.7% points. The greatest weakness of Checkpoint Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 63% points.

The company's Economic Capital Ratio, given in the ranking table, is 138%, being 112% points below the market average of 250%.

| Input Variable                              | Value in<br>1000 USD | Output Variable             | Value in<br>1000 USD |
|---------------------------------------------|----------------------|-----------------------------|----------------------|
| Assets, Current                             | 24,899               | Assets                      | 24,899               |
| Cost of Goods Sold                          | 0                    | Liabilities                 | 13,093               |
| Intangible Assets                           | 0                    | Expenses                    | 40,246               |
| Liabilities, Current                        | 13,093               | Revenues                    | 3,506                |
| Liabilities, Non-Current                    | 0                    | Stockholders Equity         | 11,806               |
| Other Assets                                | 0                    | Net Income                  | -36,367              |
| Other Compr. Net Income                     | 0                    | Comprehensive Net Income    | -36,367              |
| Other Expenses                              | 0                    | BaseVar                     | 41,058               |
| Other Liabilities                           | 0                    | ECR before LimitedLiability | -56%                 |
| Other Net Income                            | 373                  | Economic Capital Ratio      | 138%                 |
| Other Revenues                              | 3,506                |                             |                      |
| Property and Equipment                      | 0                    |                             |                      |
| Research and Development                    | 33,654               |                             |                      |
| Selling, General and Administrative Expense | 6,592                |                             |                      |